Drug manufacturers yesterday defended the legality of their restrictions on 340B contract pharmacy, in the wake of cease and desist letters from the U.S. Health Resources and Services Administration (HRSA).
Groups and individuals representing 340B covered entities, meanwhile, praised HRSA
…
U.S. Health Resources and Services Administration (HRSA) Acting Administrator Diana Espinosa this morning informed six pharmaceutical manufacturers that their restrictions on 340B program pricing to covered entities that dispense medications through contract pharmacies have resulted in overcharges and are in
…
The U.S. Centers for Medicare & Medicaid Services (CMS) Tuesday asked the White House to review a hospital payment proposed rule for next year that will either keep, end, or change the nearly 30 percent cut since 2018 in Medicare
…
Novo Nordisk’s claim that a federal legal advisory opinion on 340B contract pharmacy would make it unlawfully transfer its drugs to ineligible pharmacies and ineligible patients “is mere legerdemain” (slight of hand), government lawyers for U.S. Health and Human Services
…
United Therapeutics is holding off on requiring 340B covered entities to turn over their contract pharmacy claims data in order to get 340B pricing on drugs shipped to those pharmacies. The policy was supposed to take effect today. It will
…
U.S. Health and Human Services (HHS) Secretary Xavier Becerra told a member of Congress during a hearing this morning “We are on this one” when asked about six drug manufacturers’ denials of 340B drug discounts when covered entities use contract
…
Drug manufacturer Takeda’s designated specialty pharmacy and distributor for its leukemia drug Iclusig is making 340B covered entities declare on a form whether they will opt in or opt out of 340B pricing on purchases, as a condition for obtaining
…
The U.S. Health Resources and Services Administration (HRSA) yesterday asked the White House for permission to rescind the Trump administration’s final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers
…
Drug manufacturer Eli Lilly yesterday asked a federal district judge in Indianapolis to schedule oral argument as soon as mid-June in its lawsuit challenging both a federal legal advisory opinion about 340B contract pharmacy and the 340B program’s new administrative
…*Sign up for news summaries and alerts from 340B Report